Cancer patients in clinical trials donate various human samples (e.g., serum, plasma, blood,
urine, feces, bile, saliva) for research purposes.
The purpose of this study is to conduct further analyses on these existing samples from
clinical trials that are being performed outside of, but in collaboration with, the National
Cancer Institute.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00339664.
Various human samples (e.g., serum, plasma, whole blood, erythrocytes, urine, feces, bile,
and/or saliva) will be collected from cancer patients enrolled on approved clinical trials,
in accordance with the local protocol. These trials are being conducted at outside
institutions, in collaboration with the National Cancer Institute (NCI) and the samples will
be sent to the NCI for pharmacological analysis, involving determination of parent drug
and/or metabolite concentrations and subsequent pharmacokinetics and statistical data
analysis. This study aims to further characterize the clinical pharmacokinetic behavior of
select cancer therapeutics. Future collaborators will be added via the protocol amendment
procedure.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationNational Cancer Institute
Principal InvestigatorWilliam Douglas Figg
